Results 1 to 10 of about 7,067 (110)

Uncovering the glutamate carboxypeptidase II microenvironment using a multi-labeling proteomic approach [PDF]

Scientific Reports
Glutamate carboxypeptidase II (GCPII) is a membrane-bound metallopeptidase predominantly expressed in neural and prostatic tissues, with significantly elevated levels in prostate carcinoma that increase with tumor grade.
Jana Pokorná, Martin Hadzima, Alena Křenková, Joshua D. Smith, Vladimír Šubr, Robin Kryštůfek, Martin Hubálek, Jana Starková, Karolína Šrámková, Tomáš Etrych, Libor Kostka, František Sedlák, Jan Konvalinka, Pavel Šácha   +13 more
doaj   +4 more sources

D-DOPA Is a Potent, Orally Bioavailable, Allosteric Inhibitor of Glutamate Carboxypeptidase II [PDF]

Pharmaceutics, 2022
Glutamate carboxypeptidase-II (GCPII) is a zinc-dependent metalloenzyme implicated in numerous neurological disorders. The pharmacophoric requirements of active-site GCPII inhibitors makes them highly charged, manifesting poor pharmacokinetic (PK ...
Sadakatali S. Gori, Ajit G. Thomas, Arindom Pal, Robyn Wiseman, Dana V. Ferraris, Run-duo Gao, Ying Wu, Jesse Alt, Takashi Tsukamoto, Barbara S. Slusher, Rana Rais   +10 more
doaj   +2 more sources

Glutamate Carboxypeptidase II in Aging Rat Prefrontal Cortex Impairs Working Memory Performance [PDF]

Frontiers in Aging Neuroscience, 2021
Glutamate carboxypeptidase II (GCPII) expression in brain is increased by inflammation, and reduces NAAG (N-acetyl aspartyl glutamate) stimulation of mGluR3 signaling.
Dibyadeep Datta, Shannon N. Leslie, Elizabeth Woo, Nishita Amancharla, Ayah Elmansy, Miguel Lepe, Adam P. Mecca, Barbara S. Slusher, Angus C. Nairn, Amy F. T. Arnsten   +9 more
doaj   +2 more sources

Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Introduction Current approaches for treating sporadic Alzheimer's disease (sAD) focus on removal of amyloid beta 1‐42 (Aβ1‐42) or phosphorylated tau, but additional strategies are needed to reduce neuropathology at earlier stages prior to neuronal damage.
Shveta Bathla, Dibyadeep Datta, Feng Liang, Nicolas Barthelemy, Robyn Wiseman, Barbara S Slusher, Jennifer Asher, Caroline Zeiss, Dil Ekanayake‐Alper, Daniel Holden, Gordon Terwilliger, Alvaro Duque, Jon Arellano, Christopher van Dyck, Randall J. Bateman, Zhongcong Xie, Angus C. Nairn, Amy F. T. Arnsten   +17 more
doaj   +2 more sources

Expression of glutamate carboxypeptidase II in the glial tumor recurrence evaluated in vivo using radionuclide imaging [PDF]

Scientific Reports, 2022
Glutamate carboxypeptidase II (GCP), also known as prostate specific membrane antigen (PSMA) has been found to be expressed in glioma vasculature in in-vitro studies. GCP expression can be traced with the use of [68Ga]Ga-PSMA-11 PET/CT used routinely for
Jolanta Kunikowska, Rafał Czepczyński, Dariusz Pawlak, Henryk Koziara, Kacper Pełka, Leszek Królicki   +5 more
doaj   +2 more sources

Metabolite differences between glutamate carboxypeptidase II gene knockout mice and their wild-type littermates after traumatic brain injury: a 7-tesla 1H-MRS study [PDF]

BMC Neuroscience, 2018
Background Traumatic brain injury (TBI) is a complex condition and remains a prominent public and medical health issue in individuals of all ages. A rapid increase in extracellular glutamate occurs after TBI, leading to glutamate-induced excitotoxicity ...
Wenbo Wu, Siyi Xu, Jialin Wang, Kuiming Zhang, Mingkun Zhang, Yang Cao, Hongqing Ren, Deyou Zheng, Chunlong Zhong   +8 more
doaj   +2 more sources

Targeting glutamate carboxypeptidase II in IBD. [PDF]

Adv Pharmacol
Over the past decade, the zinc metalloenzyme glutamate carboxypeptidase (GCPII) has emerged as a novel therapeutic target for IBD. This enzyme is minimally expressed in healthy ileum or colon, but is profoundly upregulated in multiple IBD subtypes including: adult and pediatric Crohn's disease (CD), adult and pediatric ulcerative colitis (UC), and UC ...
Peters DE.
europepmc   +3 more sources

Glutamate carboxypeptidase II inhibition behaviorally and physiologically improves pyridoxine-induced neuropathy in rats. [PDF]

PLoS ONE, 2014
Pyridoxine is used as a supplement for treating conditions such as vitamin deficiency as well as neurological disorders such as depression, epilepsy and autism.
Michelle C Potter, Krystyna M Wozniak, Noelle Callizot, Barbara S Slusher   +3 more
doaj   +2 more sources

Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain [PDF]

Neurobiology of Disease, 2016
Astrocyte dysfunction and excessive activation of glutamatergic systems have been implicated in a number of neurologic disorders, including periventricular leukomalacia (PVL) and cerebral palsy (CP).
Zhi Zhang, Bassam Bassam, Ajit G. Thomas, Monica Williams, Jinhuan Liu, Elizabeth Nance, Camilo Rojas, Barbara S. Slusher, Sujatha Kannan   +8 more
doaj   +2 more sources

Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII [PDF]

FEBS Open Bio, 2017
Glutamate carboxypeptidase II (GCPII), also known as prostate‐specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate.
Tomáš Knedlík, Barbora Vorlová, Václav Navrátil, Jan Tykvart, František Sedlák, Šimon Vaculín, Miloslav Franěk, Pavel Šácha, Jan Konvalinka   +8 more
doaj   +2 more sources